Annovis Bio, Inc. (ANVS) Research

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.

Market snapshot

Symbol
ANVS
Price
$1.75
Day change
+0.57%
Market cap
$34.4M
P/E ratio
-1.19x
52-week range
1.54-5.5
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$25.67

Peer companies

  • Actinium Pharmaceuticals, Inc. (ATNM)
  • BioAtla, Inc. (BCAB)
  • BioXcel Therapeutics, Inc. (BTAI)
  • Celularity Inc. (CELU)
  • Elutia Inc. (ELUT)
  • Evaxion Biotech A/S (EVAX)
  • MAIA Biotechnology, Inc. (MAIA)
  • PDS Biotechnology Corporation (PDSB)

Recent insider activity

  • Hoffman Michael B — P-Purchase (54933 shares) on 2026-05-20
  • Hoffman Michael B — P-Purchase (18849 shares) on 2026-05-20
  • Hoffman Michael B — P-Purchase (2562 shares) on 2026-05-20
  • Hoffman Michael B — P-Purchase (713800 shares) on 2026-04-02
  • Hoffman Michael B — P-Purchase (15000 shares) on 2025-12-08

Open Annovis Bio, Inc. (ANVS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.